Piscataway, NJ, July 9, 2024 – Approximately 3.2 million Americans are affected by schizophrenia, while 5.7 million struggle with bipolar disorders. Camber Pharmaceuticals is proud to expand its product line with Quetiapine Tablets, USP, offering patients a high-quality treatment option. This addition supports our ongoing commitment to reducing drug shortages and improving access to essential medications.
Quetiapine Tablets, USP are an atypical antipsychotic indicated for the treatment of:
-
- Schizophrenia
- Bipolar I disorder, manic episodes
- Bipolar disorder, depressive episodes
Quetiapine Tablets, USP are available in:
| Strengths | Count Size(s) |
| 25 mg | 100 |
| 50 mg | 100 |
| 100 mg | 100 |
| 200 mg | 100 |
| 300 mg | 60, 100 |
| 400 mg | 100, 500 |
To learn more about Quetiapine Tablets, USP, please visit https://www.camberpharma.com/quetiapine
